Cargando…
Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
Novel drug availability has increased the depth of response and revolutionised the outcomes of multiple myeloma patients. Minimal residual disease evaluation is a surrogate for progression-free survival and overall survival and has become widely used not-only in clinical trials but also in daily pat...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Tech Science Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229300/ https://www.ncbi.nlm.nih.gov/pubmed/37305387 http://dx.doi.org/10.32604/or.2023.028668 |